

**Biocon Limited**

20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T: 91 80 2808 2808  
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/TG/2025-26/15

April 23, 2025

To, The Secretary <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Secretary <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
<b>Scrip Code – 532523</b>	<b>Scrip Symbol - Biocon</b>

Dear Sir/Madam,

**Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors at its meeting held today, i.e. on Wednesday, April 23, 2025, has inter-alia, considered and approved the following:

**1. Fund Raising:**

Raising of funds by way of issuance any instrument or security, including equity shares, non-convertible debt instruments along with warrants, any other convertible securities or any other eligible securities or any combination thereof (“Securities”), by way of qualified institutions placement(s), rights issue, preferential allotment or private placement(s) and/or any combination thereof or any other method as may be permitted under applicable laws, and on such terms and conditions as may be considered appropriate by the Board in its absolute discretion under applicable laws, for an aggregate amount of up to ₹ 4,500 crores, in one or more tranches and/or one or more issuances, subject to the receipt of necessary approvals including approval of the Shareholders of the Company and other regulatory / statutory approvals, as may be required, in this regard.

**2. Increase in Authorised Share Capital and consequential amendment to the Memorandum of Association of the Company:**

Increase in authorised share capital of the Company from existing ₹ 6,25,00,00,000 (Rupees Six Hundred Twenty Five Crores only) divided into 1,25,00,00,000 (One Hundred Twenty Five Crores)



Equity Shares of ₹ 5/- (Rupees Five only) each to ₹ 7,00,00,00,000 /- (Rupees Seven Hundred Crores only) divided into 1,40,00,00,000 (One Hundred Forty Crores) Equity Shares of ₹ 5/- (Rupees Five only) each and consequential amendment in the Capital Clause of the Memorandum of Association of the Company, subject to the receipt of necessary approvals including approval of the Shareholders of the Company and other regulatory / statutory approvals, as may be required, in this regard.

In connection with the above, the Company shall seek the requisite approval from its Shareholders through Postal Ballot. The Postal Ballot Notice will be communicated in due course.

The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155, dated November 11, 2024, is given as “**Annexure I**”.

The above-mentioned information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Further, the Board Meeting commenced at 5:00 PM and concluded at 6:20 PM.

Kindly take the above information on record and acknowledge.

Thanking You,

For **Biocon Limited**

---

**Siddharth Mittal**  
**Managing Director & CEO**  
**DIN: 03230757**

**Encl. as above**

**ANNEXURE I**

**Details under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155, dated November 11, 2024:**

<b>Sl. No.</b>	<b>Particulars</b>	<b>Details</b>
1.	Type of securities proposed to be issued (viz., equity shares, convertibles, etc.)	Such instrument or security as may be decided by the Board of Directors of the Company or any Committee thereof (" <b>Board</b> ") including Equity Shares, non-convertible debt instruments along with warrants, any other convertible securities or any other eligible securities or any combination thereof in accordance with the applicable laws (" <b>Securities</b> "), in one or more tranches and/or one or more issuances.
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR / GDR), qualified institutions placement, preferential allotment etc.)	Qualified Institutions Placement ("QIP") in accordance with the provisions of Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, rights issue, preferential allotment, private placement(s) and/or any combination thereof or any other method as may be permitted under applicable laws.
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Issuance of Securities up to an aggregate amount of ₹ 4,500 crores, in one or more tranches and/or by way of one or more issuances.
4.	In case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s): i. names of the investors ii. post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors iii. in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	To be determined by the Board or any Committee thereof as per the requirements prescribed under applicable law, at the appropriate time.
5.	In case of bonus issue the listed entity shall disclose the following additional details to the stock exchange(s):	Not applicable.

	<ul style="list-style-type: none"> <li>i. whether bonus is out of free reserves created out of profits or share premium account</li> <li>ii. bonus ratio</li> <li>iii. details of share capital -pre and post bonus issue</li> <li>iv. free reserves and/ or share premium required for implementing the bonus issue</li> <li>v. free reserves and/ or share premium available for capitalization and the date as on which such balance is available</li> <li>vi. whether the aforesaid figures are audited</li> <li>vii. estimated date by which such bonus shares would be credited/dispatched</li> </ul>	
6.	<p>In case of issuance of depository receipts (ADR/GDR) or FCCB the listed entity shall disclose following additional details to the stock exchange(s):</p> <ul style="list-style-type: none"> <li>i. name of the stock exchange(s) where ADR/GDR/FCCBs are listed (opening – closing status) / proposed to be listed</li> <li>ii. proposed no. of equity shares underlying the ADR/GDR or on conversion of FCCBs</li> <li>iii. proposed date of allotment, tenure, date of maturity and coupon offered, if any of FCCB's</li> <li>iv. issue price of ADR/GDR/FCCBs (in terms of USD and in INR after considering conversion rate)</li> <li>v. change in terms of FCCBs, if any</li> <li>vi. details of defaults, if any, by the listed entity in payment of coupon on FCCBs &amp; subsequent updates in relation to the default, including the details of the corrective measures undertaken (if any)</li> </ul>	Not applicable.
7.	<p>In case of issuance of debt securities or other non-convertible securities the listed entity shall disclose following additional details to the stock exchange(s):</p> <ul style="list-style-type: none"> <li>i. size of the issue</li> <li>ii. whether proposed to be listed? If yes, name of the stock exchange(s)</li> <li>iii. tenure of the instrument -date of allotment and date of maturity</li> </ul>	To be determined by the Board or any Committee thereof as per the requirements prescribed under applicable law, at the appropriate time.

	iv. coupon/interest offered, schedule of payment of coupon/interest and principal v. charge/security, if any, created over the assets; vi. special right/interest/privileges attached to the instrument and changes thereof vii. delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal viii. details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and /or the assets along with its comments thereon, if any; ix. details of redemption of preference shares indicating the manner of redemption (whether out of profits or out of fresh issue) and debentures	
8.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not applicable.